A bill to prohibit sales and the issuance of licenses for the export of certain defense articles to the United Arab Emirates, and for other purposes.

Senate Bill

S. 935

119th Congress

A bill to prohibit sales and the issuance of licenses for the export of certain defense articles to the United Arab Emirates, and for other purposes.

In Committee

Introduced:Nov 4, 2025

Primary Sponsor

Chris Van Hollen

Senator

Democratic

MD

Cosponsors

3

Quick Stats

Policy Area

Health

Summary

This bill would require drug manufacturers to report detailed information about certain prescription drug price increases, such as the percentage increase, justification, price history, and development costs. The Food and Drug Administration would then publish this information publicly.

Latest Action

Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

SponsorChris Van Hollen (D-MD)

Introduced11/4/2025

StatusRead twice and referred to the Committee on Foreign Relations.

ChamberSenate

Data from Congress.gov

See this page through your district lens

Enter ZIP to personalize representatives and vote context.

Stay on top of this issue

Subscribe for weekly bill and representative updates.

Vote Prediction

A bill to prohibit sales and the issuance of licenses for the export of certain defense articles to the United Arab Emirates, and for other purposes.

This bill would require drug manufacturers to report detailed information about certain prescription drug price increases, such as the percentage increase, justification, price history, and development costs. The Food and Drug Administration would then publish

Community Breakdown

Pass

0%

Fail

0%

0 predictions

This bill would require drug manufacturers to report detailed information about certain prescription drug price increases, such as the percentage increase, justification, price history, and development costs. The Food and Drug Administration would then publish this information publicly.

Bill Number: 935
Sponsor: Chris Van Hollen (D-MD)
Introduced: 11/4/2025
Status: Read twice and referred to the Committee on Foreign Relations.
Policy Area: Health

Data from Congress.gov

AI-generated summary

Fact Sheet

Title: A bill to prohibit sales and the issuance of licenses for the export of certain defense articles to the United Arab Emirates, and for other purposes.
Bill Number: 935
Sponsor: Chris Van Hollen (D-MD)
Status: Read twice and referred to the Committee on Foreign Relations.
Introduced: 11/4/2025
Summary: This bill would require drug manufacturers to report detailed information about certain prescription drug price increases, such as the percentage increase, justification, price history, and development costs. The Food and Drug Administration would then publish this information publicly.

Data from Congress.gov

AI Summary

Plain-English explanation of this bill

This bill would require drug manufacturers to report detailed information about certain prescription drug price increases, such as the percentage increase, justification, price history, and development costs. The Food and Drug Administration would then publish this information publicly.

Last updated: 12/29/2025

Official Summary

Congressional Research Service summary

Fair Accountability and Innovative Research Drug Pricing Act of 2023 This bill requires manufacturers to report about certain price increases for prescription drugs and biological products with a wholesale cost of at least $100 per month. Such reports must include, among other information (1) the percentage price increase, (2) a justification for such increase, (3) the price history of the drug, (4) the total cost to develop the drug, and (5) the total revenue and net profit generated from the drug. Manufacturers are subject to civil penalties for failing to comply with the bill's requirements. Additionally, the Food and Drug Administration must post the information on its website.

Key Points

Main provisions of the bill

Drug manufacturers would have to report information about price increases for prescription drugs costing at least $100 per month.
Reported details would include the percentage price increase, reasons for the increase, the drug's price history, development costs, and revenue and profits.
The FDA would be required to publish this drug pricing information on its website.
Manufacturers that fail to comply could face civil penalties.
The goal is to increase transparency around prescription drug pricing.

How This Impacts Americans

Potential effects on citizens and communities

This bill would primarily affect drug manufacturers, who would have new reporting requirements. It could also impact consumers, insurers, and policymakers by providing more information about the reasons behind rising prescription drug costs. Greater transparency could lead to increased public scrutiny and pressure on the pharmaceutical industry.

Policy Areas

Primary Policy Area

Health

Scope & Jurisdiction

Jurisdiction Level

federal

Congressional Session

119th Congress

Citation Reference

935, 119th Congress (2025). "A bill to prohibit sales and the issuance of licenses for the export of certain defense articles to the United Arab Emirates, and for other purposes.". Source: Voter's Right Platform. https://votersright.org/bills/118-s-935